Inspire Medical Systems (INSP) Q1 2025 Earnings Call May 05, 2025 05:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor RelationsTim Herbert - Chairman, President & CEORick Buchholz - CFOTravis Steed - Managing Director - Equity ResearchRichard Newitter - Managing DirectorChris Pasquale - Partner - Medical Devices & SuppliesAnthony Petrone - Managing DirectorJonathan Block - Managing DirectorBrett Gasaway - VP - Equity Research Conference Call Participants Danielle Antalffy - AnalystRober ...

Inspire Medical Systems (INSP) Q1 2025 Earnings Call May 05, 2025 05:00 PM ET Speaker0 Good afternoon. My name is Dilem, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Inspire Medical Systems First Quarter twenty twenty five Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers remarks, there'll be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. Y ...

Inspire Medical Systems, Inc. May 2025 NYSE: INSP Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ''may,'' ''will,'' ''should,'' ''expect,'' ''plan,'' ''anticipate,'' ''could,'' "future," "outlook," ''intend,'' ''target,'' ''project,'' ''contemplate,'' ' ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q ________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38468 ______________________________ Inspire ...

Recent Business Highlights "We are very proud of our performance in the first quarter which included strong revenue growth and continued progress on profitability. We achieved a tremendous milestone with over 100,000 patients receiving Inspire therapy and we are still just getting started in growing awareness and adoption," said Tim Herbert, Chairman and CEO of Inspire Medical Systems. "We are now ready to launch of the Inspire V system and look forward to initiating the full launch this month in the U.S." ...

Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2025. Recent Business Highlights Generated revenue of $201.3 ...

For additional information about Inspire, please visit www.inspiresleep.com. Investor and Media Contact Ezgi Yagci Vice President, Investor Relations ezgiyagci@inspiresleep.com 617-549-2443 About Inspire Medical Systems Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technolo ...

文章核心观点 公司将于5月5日盘后公布2025年第一季度财务结果，并于美东时间下午5点召开电话会议讨论财务结果和业务发展情况 [1] 财务结果公布与会议安排 - 公司将于5月5日盘后公布2025年第一季度财务结果 [1] - 管理层将于美东时间下午5点召开电话会议讨论财务结果和业务发展 [1] 会议参与方式 - 可通过公司网站投资者关系页面或指定链接观看网络直播，不提问者建议使用此方式 [2] - 提问者需通过指定链接注册，注册后会收到包含拨入详情和接入码的邮件，建议提前10分钟注册 [3] 会议回放信息 - 会议结束约两小时后可在公司投资者关系网站查看回放，回放将存档两周 [4] 公司简介 - 公司是专注于开发和商业化阻塞性睡眠呼吸暂停微创解决方案的医疗技术公司 [5] - 公司的Inspire疗法是首个且唯一获FDA、欧盟MDR和PDMA批准的神经刺激技术，可治疗中重度阻塞性睡眠呼吸暂停 [5] 投资者与媒体联系方式 - 投资者关系副总裁Ezgi Yagci，邮箱ezgiyagci@inspiresleep.com，电话617 - 549 - 2443 [6]

文章核心观点 医疗技术公司Inspire Medical Systems管理层将于2025年3月18日在KeyBanc Capital Markets医疗保健论坛上进行展示 [1] 公司信息 - 公司专注于为阻塞性睡眠呼吸暂停患者开发和商业化创新、微创解决方案 [1][3] - 公司专有的Inspire疗法是首个且唯一获FDA、欧盟MDR和PDMA批准的神经刺激技术，可安全有效地治疗中重度阻塞性睡眠呼吸暂停 [3] 展示安排 - 展示时间为美国东部时间下午3点 [2] - 可通过直播网络广播观看展示 [2] - 展示结束后两周内，可在公司投资者网站的活动存档部分观看网络广播回放 [2] 联系方式 - 投资者和媒体联系人：Ezgi Yagci，投资者关系副总裁 [4] - 联系邮箱：ezgiyagci@inspiresleep.com [4] - 联系电话：617 - 549 - 2443 [4]

文章核心观点 - Zacks Premium为投资者提供多种利用股市和自信投资的方式 ，其研究服务包含每日更新的Zacks Rank和Zacks Industry Rank等 ，还包括Zacks Style Scores ，Style Scores与Zacks Rank配合使用可帮助投资者挑选股票 ，如Inspire Medical Systems就因排名和评分表现值得投资者关注 [1][2][13] Zacks Premium研究服务 - 提供每日更新的Zacks Rank和Zacks Industry Rank ，可全面访问Zacks 1 Rank List 、Equity Research reports和Premium stock screens ，帮助投资者更明智自信地投资 [1] - 包含Zacks Style Scores [1] Zacks Style Scores介绍 - 与Zacks Rank一同开发 ，是基于三种投资方法对股票进行评级的补充指标 ，帮助投资者挑选未来30天跑赢市场可能性最大的股票 [2] - 每只股票根据价值 、增长和动量特质被给予A - F的字母评级 ，评分越高股票表现越好 [3] - 分为价值 、增长 、动量和VGM四个类别 [3] Zacks Style Scores类别 价值评分 - 价值投资者喜欢低价买入优质股票 ，价值评分利用P/E 、PEG等比率识别最具吸引力和折扣最大的股票 [3] 增长评分 - 增长投资者关注公司财务实力 、健康状况和未来前景 ，增长评分通过考察预计和历史收益 、销售和现金流等寻找可持续增长的股票 [4] 动量评分 - 动量交易利用股票价格或收益前景的涨跌趋势 ，动量评分通过一周价格变化和收益估计月百分比变化等因素确定建仓时机 [5] VGM评分 - 综合三种评分 ，根据加权风格对股票评级 ，帮助找到价值 、增长和动量最佳的公司 ，是与Zacks Rank配合使用的最佳指标之一 [6] Style Scores与Zacks Rank配合 - Zacks Rank是利用收益估计修正来构建投资组合的股票评级模型 ，自1988年以来 ，1（强力买入）股票平均年回报率达+25.41% ，但每日有超800只高评级股票 ，挑选合适股票有难度 [7][8] - Style Scores可辅助挑选股票 ，应选择Zacks Rank为1或2且Style Scores为A或B的股票 ，若为3（持有）评级也需确保分数为A或B ，而4（卖出）或5（强力卖出）评级股票即便分数为A和B也可能下跌 [9][10] 股票案例：Inspire Medical Systems - 是专注于阻塞性睡眠呼吸暂停创新微创解决方案的医疗技术公司 ，其Inspire系统是首个获FDA批准的神经刺激技术 ，有大量临床数据支持其疗法的安全性和有效性 [11] - Zacks Rank为2（买入） ，VGM Score为A ，动量风格评分为B ，过去四周股价上涨1.1% ，2025财年有七位分析师上调收益估计 ，Zacks共识估计提高0.12美元至每股2.16美元 ，平均收益惊喜为332.5% ，值得投资者关注 [12][13]